Stock Scorecard

Stock Summary for Black Diamond Therapeutics Inc (BDTX) - $2.43 as of 11/20/2024 7:06:43 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BDTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BDTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BDTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BDTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BDTX (28 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for BDTX

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences 11/1/2024 12:00:00 PM
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug - Black Diamond Therapeutic ( NASDAQ:BDTX ) 9/23/2024 3:43:00 PM
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations 9/23/2024 11:00:00 AM
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Black Diamond Therapeutic ( NASDAQ:BDTX ) 9/22/2024 2:00:00 PM
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC 9/22/2024 2:00:00 PM
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology ( ESMO ) Congress 2024 9/14/2024 7:30:00 AM
Looking Into Black Diamond Therapeutic's Recent Short Interest - Black Diamond Therapeutic ( NASDAQ:BDTX ) 8/22/2024 1:15:00 PM
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update 8/13/2024 10:00:00 AM
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting 6/1/2024 2:00:00 PM
Should You Buy Black Diamond Therapeutics ( BDTX ) Ahead of Earnings? 5/10/2024 12:46:00 PM

Financial Details for BDTX

Company Overview
Ticker BDTX
Company Name Black Diamond Therapeutics Inc
Country USA
Description Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 2.43
Price 4 Years Ago 32.05
Last Day Price Updated 11/20/2024 7:06:43 PM EST
Last Day Volume 470,096
Average Daily Volume 647,271
52-Week High 7.66
52-Week Low 2.15
Last Price to 52 Week Low 13.02%

Valuation Measures
Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -4.76
Free Cash Flow Ratio 1.22
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 5.55
Total Cash Per Share 1.99
Book Value Per Share Most Recent Quarter 1.72
Price to Book Ratio 1.45
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 56,585,000
Market Capitalization 137,501,550
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 9.57%
Reported EPS 12 Trailing Months -1.33
Reported EPS Past Year -0.99
Reported EPS Prior Year -1.88
Net Income Twelve Trailing Months -73,099,000
Net Income Past Year -82,442,000
Net Income Prior Year -91,169,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet
Total Cash Most Recent Quarter 112,682,000
Total Cash Past Year 131,400,000
Total Cash Prior Year 122,807,000
Net Cash Position Most Recent Quarter 112,682,000
Net Cash Position Past Year 131,400,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 116,736,000
Total Stockholder Equity Prior Year 115,695,000
Total Stockholder Equity Most Recent Quarter 97,426,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -90,656,000
Free Cash Flow Per Share Twelve Trailing Months -1.60
Free Cash Flow Past Year -66,750,000
Free Cash Flow Prior Year -85,274,000

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.26
MACD Signal -0.24
20-Day Bollinger Lower Band 1.88
20-Day Bollinger Middle Band 4.55
20-Day Bollinger Upper Band 7.22
Beta 2.52
RSI 30.96
50-Day SMA 3.28
150-Day SMA 0.00
200-Day SMA 6.21

System
Modified 11/20/2024 7:07:29 PM EST